ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 860

Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis

Fatma Alibaz-Oner1, Matthew J. Koster2, Ali Ugur Unal3, Hale Gulcin Yildirim4, Ceylan Cikikci4, Cynthia S. Crowson5, Ashima Makol6, Steven R. Ytterberg6, Eric L. Matteson6, Haner Direskeneli7 and Kenneth J. Warrington6, 1Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, 3Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 4Marmara University Faculty of Medicine, Istanbul, Turkey, 5Health Sciences Research, Mayo Clinic, Rochester, MN, 6Rheumatology, Mayo Clinic, Rochester, MN, 7Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, takayasu arteritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Accelerated atherosclerosis associated with chronic inflammation is one of the major complications of systemic inflammatory diseases. Takayasu arteritis (TAK) is a rare, systemic large-vessel vasculitis predominantly affecting the aorta and its major branches. The prevalence of atherosclerotic risk factors and cardiovascular (CV) disease in patients with TAK has not been well defined. The purpose of this study was to assess the frequency of CV risk factors and the incidence of CV events (CVE) in patients with TAK.

Methods: Patients fulfilling the 1990 American College of Rheumatology criteria for TAK from Mayo Clinic, Rochester, USA and Marmara University, Istanbul, Turkey were included in this retrospective cohort study. Data on CV risk factors at the time of TAK diagnosis and incident CVE during follow-up were abstracted from the medical records. Patients with TAK were compared to age, sex and calendar year–matched controls from the same geographic region without TAK. The 2008 Framingham 10-year general CV risk score (FRS) was used for the evaluation of CV risk at the time of TAK incidence/index date. For patients without lipid profiles, the office-based FRS, which does not require lipid values, was computed according to previously published algorithms.

Results: A total of 175 patients with TAK and 175 non-TAK controls were included in the study (115 from Mayo Clinic, 60 from Marmara University for each group). Among patients age ≥ 30 years at index date (107 TAK,109 non-TAK), complete data to calculate FRS were available in 93 (87%) TAK and 91 (83%) non-TAK subjects. Hypertension diagnosis and lipid-lowering treatment were significantly more frequent in the TAK group compared to non-TAK. Prior to the incidence/index date, the occurrence of CVE was significantly higher in the TAK group The overall Framingham 10-year CV risk score was significantly higher in the TAK group compared to non-TAK at incidence/index date (Table 1). After excluding patients with prevalent CVE, 18 TAK and 3 non-TAK patients developed CVE during a mean follow-up of 7.4 years in TAK and 7.9 years in non-TAK groups. The cumulative incidence of CVE was 16.4% at 10 years in TAK group vs. 6.0% in non-TAK group and the risk of CVE was increased among patients with TAK (hazard ratio: 4.52; 95% CI: 1.29, 15.78 adjusted for age, sex and country).

TAK table.JPG

Conclusion: CV risk factors are more common in patients with TAK, and the Framingham 10-year cardiovascular risk score is higher in patients with TAK at the time diagnosis compared to non-TAK subjects of similar age and sex. The cumulative incidence of CVE was also significantly higher during follow-up in the TAK group. Patients with TAK should undergo careful assessment of CV risk factors, and an aggressive risk modification approach is warranted.


Disclosure: F. Alibaz-Oner, None; M. J. Koster, None; A. U. Unal, None; H. G. Yildirim, None; C. Cikikci, None; C. S. Crowson, None; A. Makol, None; S. R. Ytterberg, None; E. L. Matteson, None; H. Direskeneli, None; K. J. Warrington, None.

To cite this abstract in AMA style:

Alibaz-Oner F, Koster MJ, Unal AU, Yildirim HG, Cikikci C, Crowson CS, Makol A, Ytterberg SR, Matteson EL, Direskeneli H, Warrington KJ. Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/assessment-of-the-frequency-of-cardiovascular-risk-factors-in-patients-with-takayasus-arteritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-frequency-of-cardiovascular-risk-factors-in-patients-with-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology